Drug intelligence / Profile preview

TD-1607

Development stage: Phase 1
Lead developer: Theravance Biopharma
Modality: Peptides, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Intravenous

Overview

TD-1607 is a glycopeptide-cephalosporin heterodimer antibiotic developed for the treatment of serious Gram-positive bacterial infections, including methicillin-resistant *Staphylococcus aureus* (MRSA). It consists of a glycopeptide covalently linked to a cephalosporin moiety. The drug exerts its antibacterial activity by inhibiting cell wall biosynthesis through targeting penicillin-binding proteins (PBPs), resulting in rapid and potent bactericidal effects against Gram-positive organisms. TD-1607 has demonstrated strong *in vitro* activity and was evaluated in Phase I clinical trials for safety, tolerability, and pharmacokinetics.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on TD-1607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TD-1607.

Explore the full profile